Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
HutchMed Completes Patient Enrollment for Orpathys in Gastric Cancer ...
HutchMed's Orpathys Receives Priority Review for NSCLC Treatment in ...
HUTCHMED - Our Products
HutchMed's Orpathys Approved for Expanded NSCLC Indication in China ...
HutchMed's Orpathys Receives Breakthrough Therapy Designation in China ...
We are pleased to announce that the supplemental New Drug Application ...
ORPATHYS and TAGRISSO combo approved in China for lung cancer ...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso ...
HUTCHMED on LinkedIn: HUTCHMED Announces Agreement with NHSA for ...
HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC ...
We are pleased to share that the New Drug Application for the ...
HUTCHMED Receives Approval for ORPATHYS® and TAGRISSO® Combination in ...
HUTCHMED Gains China Approval for ORPATHYS® and TAGRISSO® Combo in MET ...
Hutchmed Completes Patient Enrollment for Orpathys®-Tagrisso® Lung ...
HUTCHMED Announces China Approval for ORPATHYS® in Combination with ...
Orpathys (savolitinib) Effective in EGFR-Mutant, MET-Amplified Non ...
HUTCHMED's ORPATHYS®: A Game Changer in MET Exon 14 NSCLC Treatment
HUTCHMED Announces that TAGRISSO® plus ORPATHYS® demonstrated high ...
HUTCHMED Announces Breakthrough Therapy Designation for ORPATHYS® and ...
HUTCHMED's ORPATHYS® and TAGRISSO® Combo: A Game Changer in Lung Cancer ...
China Approves Orpathys & Tagrisso Combo for Lung Cancer | Pienomial
HUTCHMED’ Orpathys (Savolitinib) Receives the NMPA’s Full Approval for ...
Orpathys approved in China for patients with lung cancer and MET gene ...
Hutchmed's Orpathys, Tagrisso NSCLC Combo Approved in China | Precision ...
HUTCHMED - HUTCHMED Reports 2025 Interim Results
HUTCHMED - HUTCHMED Reports 2024 Full Year Results and Provides ...
HUTCHMED Completes Enrollment in Global P-III (SAFFRON) Study of ...
HutchMed highlights publication of Phase III SACHI study results of ...
HUTCHMED - 上市产品
NMPA approves ORPATHYS + TAGRISSO combo in China for the Treatment of ...
We are pleased to share that the Center for Drug Evaluation of China’s ...
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
Hutchmed and AstraZeneca launch Phase 3 to test Orpathys and Tagrisso ...
Hutchmed Seeking Additional Approval in China for Orpathys in MET Exon ...
HUTCHMED completes enrolment in phase 3 trial for lung cancer - Pharmafile
HUTCHMED Completes Patient Enrollment in Phase III SANOVO Study of ...
AstraZeneca's Orpathys approved in China - Nordic Life Science – the ...
We are pleased to announce positive high-level results from the ...
AZ, HutchMed's savolitinib gets 1st approval in China for NSCLC ...
肺癌精准治疗！中国MET抑制剂：赛沃替尼(沃瑞沙，Orpathys)获批，治疗METex14突变非小细胞肺癌! - 专区 - 生物谷
沃瑞沙/ORPATHYS说明书_医药百科_医库
HUTCHMED - HUTCHMED Reports 2023 Full Year Results and Provides ...
Latest BioPharma News and In-Depth Analysis | BioPharma BoardRoom
Anticancer drugs: How to select small molecule combinations?: Trends in ...
Trinity Delta Orpathys/Tagrisso combination approved in China - Trinity ...
Massive Bio: Advancing Cancer Care with AI-Driven Clinical Trials
Hutchmed completes Saffron trial enrolment, results due 2026 ...
HUTCHMED Gains Wider NRDL Coverage and First Commercial Insurance ...
ORPATHYS (Savolitinib Tablets) - NSCLC | DengYue Medicine
NDA in China receives priority review status for lung cancer treatment
Trinity Delta On the right track - Trinity Delta
NMPA full approval for Orpathys | The Pharmaletter
HUTCHMED
MediCircle | Lancet
HUTCHMED on LinkedIn: We are delighted to announce the first commercial ...
Savolitinib Shines in HutchMed Phase II Lung Cancer Trial
和黄医药与阿斯利康启动沃瑞沙?（ORPATHYS?）治疗MET扩增胃癌患者的II期临床试验医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Trinity Delta Looking ahead to the next chapter - Trinity Delta
Fixed-duration Calquence-based regimens approved in EU for patients ...
Savolitinib's Promising Gastric Cancer Data Positions HUTCHMED for ...
和黄医药宣布沃瑞沙® (ORPATHYS®) 和泰瑞沙® (TAGRISSO®) 的联合疗法用于治疗伴有MET扩增的一线EGFR抑制剂治疗后 ...
New Data at ELCC 2025 Reinforces Tagrisso's Role in Treating EGFR ...
Imfinzi approved in the EU as first and only immunotherapy for limited ...
Trinity Delta Advancing innovation and increasing core business focus ...
Hutchmed Share Price Gapped 12% on Delayed Response to New
和黄医药宣布沃瑞沙(ORPATHYS)于中国首次商业销售 触发来自阿斯利康的2,500万美元里程碑付款医药新闻-ByDrug-一站式医药资源 ...
Hutchmed cashes in a Chinese JV to help fund its pipeline | pharmaphorum
Pharma - 𝐀𝐭 𝐄𝐋𝐂𝐂 𝟐𝟎𝟐𝟓, AstraZeneca ’s 𝐓𝐚𝐠𝐫𝐢𝐬𝐬𝐨 𝐞𝐦𝐞𝐫𝐠𝐞𝐝 𝐚𝐬 𝐭𝐡𝐞 ...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anti ...
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR ...
和黄医药(00013.HK)宣布沃瑞沙(ORPATHYS)和泰瑞沙(TAGRISSO)的联合疗法在中国获纳入突破性治疗品种用于治疗EGFR抑制 ...
Trinity Delta Significant 2022 achievements catalyse a promising 2023 ...
NDA in China receives priority review status for lung cancer treatment ...
HUTCHMED on LinkedIn: HUTCHMED has received a US$15 million milestone ...
Heather Reinhardt Hays, CPB on LinkedIn: HUTCHMED and AstraZeneca ...
These highlights do not include all the information needed to use ...
A Fast LC-MS/MS Methodology for Estimating Savolitinib in Human Liver ...
(PDF) Landscape of Savolitinib Development for the Treatment of Non ...
Osimertinib + Savolitinib Demonstrated 49% ORR in Lung Cancer Patients ...
New study results reinforce Tagrisso as the backbone therapy for EGFR ...
Trinity Delta Executing consistently on the road to breakeven - Trinity ...
AstraZeneca becomes first international company to file Medicare drug ...
Orpathys ( Savolitinib ) | 200mg | Tableta - DengYuePharma
舒尼替尼与卡博替尼、沃瑞沙/ORPATHYS（赛沃替尼/Savolitinib）治疗晚期乳头状肾癌效果哪个更好？卡博替尼仿制药中国上市了吗 ...
Orbactiv - FDA prescribing information, side effects and uses
开售|沃瑞沙(赛沃替尼)[¥8588元/盒] | 百配健康-阅读越健康!
Savolitinib Shows Promise in Gastric Cancer: Phase II Trial Completed
赛沃替尼(Savolitinib)-Orpathys说明书_药得
AstraZeneca AB Trademarks Page 6 :: Justia Trademarks
Response and acquired resistance to savolitinib in a patient with pulm ...
